Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Lenalidomide in High Risk MDS and AML
NCT01038635Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2009
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01038635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01038635.